Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 10/20 | 0.72 |
| ▸ | LDHA | P00338 | 1/20 | 0.69 |
| ▸ | PPARA | Q07869 | 7/20 | 0.61 |
| ▸ | PPARD | Q03181 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12191490 | 1.00 | PPARG (0.72) | PPARGLDHAPPARAPPARDKMT2A | |
| SCHEMBL10436394 | 0.95 | LDHA (0.76) | PPARGLDHAPPARAPPARDKMT2A | |
| SCHEMBL6177184 | 0.90 | CYP1A2 (0.69) | PPARGLDHAPPARAKMT2ACYP1A2 | |
| SCHEMBL12494157 | 0.88 | LDHA (0.71) | PPARGLDHAPPARAPPARDKMT2A | |
| SCHEMBL12493566 | 0.88 | LDHA (0.71) | PPARGLDHAPPARAPPARDKMT2A | |
| SCHEMBL10356762 | 0.87 | LDHA (0.60) | PPARGLDHAPPARAPPARDKMT2A | |
| SCHEMBL8755746 | 0.86 | AKR1C3 (0.59) | PPARGLDHAPPARAPPARDEPHX2 | |
| SCHEMBL6178867 | 0.85 | LDHA (0.67) | PPARGLDHAPPARAKMT2A | |
| SCHEMBL21194011 | 0.85 | LDHA (0.67) | PPARGLDHAPPARAPPARDKMT2A | |
| SCHEMBL11357751 | 0.85 | LDHA (0.67) | PPARGLDHAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067599-A1 | IODOTYROSINE DERIVATIVES AND PROCESS FOR PREPARING IODOTYROSINE DERIVATIVES | ABX ADVANCED BIOCHEMICAL COMPOUNDS - BIOMEDIZINISCHE FORSCHUNGSREAGENZIEN GMBH (DE) | 2024-02-29 | — | — | US | disclosed |
| US-8030279-B2 | Tamandarin analogs and fragments thereof and methods of making and using | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2011-10-04 | — | — | US | disclosed |
| US-7482484-B2 | Carboxylic acids and derivatives for the treatment of and preventing diabetes and dyslipidaemia | MERCK PATENT GMBH (DE) | 2009-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240067599-A1 | IODOTYROSINE DERIVATIVES AND PROCESS FOR PREPARING IODOTYROSINE DERIVATIVES | ALK, ALKBH3, INSR | PPARG 3840/4885LDHA 4516/4885PPARA 4834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.